利多卡因与硫酸镁联合应用对乳腺癌患者术后疼痛的协同作用:随机、双盲试验

2020-06-04 anesthGH 罂粟花

Synergisticeffect of the association between lidocaine and magnesium sulfate on peri-operative pain

背景与目的
最近,静脉辅助药物的使用,如利多卡因和硫酸镁,在多模式镇痛中得到了越来越多的应用。然而,对这两种药物联合使用产生的效果的评估尚未见报道。本研究旨在评价静脉辅助用药在降低乳腺癌患者术后阿片类药物用量和疼痛评分中的作用。
方  法
纳入198名择期接受乳房切除术的患者。78人被排除在外。术中输注瑞芬太尼(0.1 ug·kg-1。min-1)、利多卡因(3 mg·kg-1.h-1)、硫酸镁(50 mg·kg-1h+15 mg·kg-1。h-1)或利多卡因加硫酸镁。主要结果指标为围手术期阿片类药物消耗和疼痛评分。
结 果
利多卡因组+硫酸镁组(n=30)术中阿芬太尼用量较少(P<0.001),术后二吡咯酮和吗啡用量较少(P<0.001)。利多卡因加硫酸镁组仅2例患者(6.7%)需要吗啡(P<0.001)。与接受瑞芬太尼(n=30; 76.6%,OR=46.00,95%可信区间8.69%~243.25,P<0.001)和硫酸镁(n=30; 70%,OR32.66,95%可信区间6.37%~167.27,P<0.001)治疗的患者比较,术后需要吗啡的患者例数明显降低。利多卡因加硫酸镁组术后前24h内数字评分和言语评分均低于其他3组(P<0.001)。
结 论
利多卡因和硫酸镁在围手术期镇痛中有协同作用。这可能是多模式镇痛方案的另一种潜在策略。
原始文献摘要
Mendon?a FT,  Pellizzaro D,  Grossi BJ, et,al. Synergisticeffect of the association between lidocaine and magnesium sulfate on peri-operative pain after mastectomy A randomised, double-blind trial [J]. Eur J Anaesthesiol 2020 Mar;37(3) DOI:10.1097/EJA.0000000000001153
BACKGROUNDRecently, the use of venous adjuvants, such as lidocaine and magnesium sulfate, has been gaining ground in multimodal analgesia. However, no study has evaluated the impact a combination of the two drugs.
OBJECTIVES To evaluate the efficacy of venous adjuvants in reducing opioid consumption and pain scores after mastectomy.
DESIGN Randomised, double-blind, parallel-group, non-inferiority clinical trial with a 1 : 1 : 1 : 1 allocation ratio.
SETTING Hospital de Base do Distrito Federal, Brasilia,Federal District, Brazil from November 2014 to December2017.
PATIENTS One-hundred and ninety-eight patients were electively scheduled for mastectomy. Seventy-eight were excluded.
INTERVENTIONS Intra-operative infusions of remifentanil (0.1mgk g-1min-1), lidocaine (3 mg kg-1h-1), magnesium sulfate (50 mg kg-1R15 mg kg-1h-1) or lidocaine with magnesium sulfate were used. All patients received standard general anaesthesia.
MAIN OUTCOME MEASURES Peri-operative opioid consumption and pain scores.
RESULTS The patients who received both lidocaine and magnesium sulfate group (n=30) consumed less alfentanil during surgery (P<0.001) and less dipyrone (P<0.001) and morphine (P<0.001) in the postoperative period. Only two patients (6.7%) in the lidocaine and magnesium sulfate group needed morphine (P<0.001). These requirements were significantly lower when compared with patients who received remifentanil (n=30; 76.6%) and magnesium sulfate (n?30; 70%; odds ratio 46.0, 95% confidence interval 8.69 to 243.25, P<0.001, and odds ratio 32.66, 95% confidence interval 6.37 to 167.27, P<0.001, respectively). The patients of the lidocaine and magnesium sulfate group had lower pain scores in the first 24h postoperatively using the numerical rating scale and verbal rating scale at discharge from the postanaesthesia care unit (P<0.001), after 12 h(P<0.001) and after 24 h (P<0.001) when compared with the other three groups.
CONCLUSION Our findings suggest a synergistic effect of the use of both lidocaine and magnesium in peri-operative pain. This may be another potential strategy in the multimodal analgesia regimen.

相关资讯

ASCO 2020丨遗憾!早期局部治疗未能改善原发IV期乳腺癌女性的总生存率

早期局部治疗不能提高复发转移性乳腺癌和IPT患者的生存率。虽然在没有LRT的情况下,局部疾病进展的风险高出2.5倍,但IPT的LRT并没有使HRQOL得到改善。

BMJ:乳腺导管原位癌患者的浸润性乳腺癌和乳腺癌死亡风险研究

通过筛查发现乳腺导管原位癌的女性,在确诊后至少20年的时间里,比一般人群中相比具有更高的浸润性乳腺癌和乳腺癌死亡风险

Ibrance联合标准疗法治疗乳腺癌:未达到主要终点

辉瑞公司(Pfizer)近日表示,Ibrance(palbociclib)联合内分泌疗法治疗激素受体(HR)阳性/HER2阴性的早期乳腺癌患者时,未能显著改善无病生存期(DFS)(研究的主要终点)。

ASCO 2020:HR+/HER2-晚期乳腺癌内脏转移时治疗的选择?

原发耐药、内脏转移都是HR+/HER2-晚期乳腺癌预后不良的因素,也是单独内分泌治疗难以克服的顽疾。既往的研究已经证实氟维司群在晚期内分泌治疗中的疗效,其与CDK4/6抑制剂(CDK4/6i)的强强联

Nat Cell Bio:晚期乳腺癌患者中找到一种神秘蛋白,有望治疗乳腺癌

导言:目前乳腺癌的病因尚未明确,早期乳腺癌往往不具备典型的症状和体征,不易引起重视,但乳腺癌的发病率位居女性恶性肿瘤之首,因此女性往往谈之色变。乳腺癌的早发现、早诊断是提高疗效的关键。最近南澳大利亚的

SCIENCE:循环肿瘤细胞通过核糖体蛋白指向肿瘤转移

循环肿瘤细胞(CTCs)从原发肿瘤脱落到血液中,但其中只有一小部分细胞产生转移。